Aristotle Atlantic Partners, LLC Iovance Biotherapeutics, Inc. Transaction History

Aristotle Atlantic Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$5.36 - $9.06 $1.08 Million - $1.82 Million	201,252 Added 19.79%	1,218,025 $8.57 Million
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $46,103 - $68,530	8,337 Added 0.83%	1,016,773 $6.21 Million
Q4 2022 Feb 14, 2023	SELL	$5.62 - $10.0 $46,157 - $82,130	-8,213 Reduced 0.81%	1,008,436 $6.44 Million
Q3 2022 Nov 14, 2022	BUY	$9.53 - $13.11 $55,655 - $76,562	5,840 Added 0.58%	1,016,649 $9.74 Million
Q2 2022 Aug 15, 2022	BUY	$6.38 - $18.33 $3.08 Million - $8.86 Million	483,393 Added 91.65%	1,010,809 $11.2 Million
Q1 2022 May 16, 2022	BUY	$12.38 - $19.1 $23,249 - $35,869	1,878 Added 0.36%	527,416 $8.78 Million
Q4 2021 Feb 14, 2022	BUY	$16.55 - $27.63 $8.7 Million - $14.5 Million	525,538 New	525,538 $10 Million

320

238M

1.27M

1.68M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.74B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Aristotle Atlantic Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Aristotle Atlantic Partners, LLC with notifications on news.